Development and Validation of Stability-indicating High Performance Liquid Chromatographic Method for the Estimation of Everolimus in Tablets

被引:0
作者
Sharmila, D. [1 ]
Rao, A. Lakshmana [1 ]
Kalyani, L. [1 ]
机构
[1] Vallabhaneni Venkatadri Inst Pharmaceut Sci, Krishna 521356, Gudlavalleru, India
关键词
Everolimus; reversed-phase high performance liquid chromatographic; stability; validation;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present study depicts the development of a validated reversed-phase high performance liquid chromatographic method for the determination of the everolimus in presence of degradation products or pharmaceutical excipients. Stress study was performed on everolimus and it was found that it degrade sufficiently in oxidizing and acidic conditions but less degradation was found in alkaline, neutral, thermal and photolytic conditions. The separation was carried out on Hypersil BDS C18 column (100x4.6 mm, 5 mu) column having particle size 5 mu using acetate buffer: acetonitrile (50: 50 v/v) with pH 6.5 adjusted with orthophosphoric acid as mobile phase at flow rate of 1 ml/min. The wavelength of the detection was 280 nm. A retention time (R-t) nearly 3.110 min was observed. The calibration curve for everolimus was linear (r(2)=0.999) from range of 25-150 mu g/ml with limit of detection and limit of quantification of 0.036 mu g/ml and 0.109 mu g/ml, respectively. Analytical validation parameters such as selectivity, specificity, linearity, accuracy and precision were evaluated and relative standard deviation value for all the key parameters were less than 2.0%. The recovery of the drug after standard addition was found to be 100.55%. Thus, the developed RP-HPLC method was found to be suitable for the determination of everolimus in tablets containing various excipients.
引用
收藏
页码:599 / 604
页数:6
相关论文
共 16 条
[1]  
[Anonymous], 2005, Quality Risk Management Q9, P1
[2]  
[Anonymous], 2003, INT C HARMONISATION, P1
[3]   Everolimus [J].
Atkins, Michael B. ;
Yasothan, Uma ;
Kirkpatrick, Peter .
NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (07) :535-536
[4]   Development of validated stability-indicating assay methods - critical review [J].
Bakshi, M ;
Singh, S .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 28 (06) :1011-1040
[5]   Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection [J].
Baldelli, S ;
Zenoni, S ;
Merlini, S ;
Perico, N ;
Cattaneo, D .
CLINICA CHIMICA ACTA, 2006, 364 (1-2) :354-358
[6]  
Buchwald Armin, 2012, BMC Clin Pharmacol, V12, P2, DOI 10.1186/1472-6904-12-2
[7]   Everolimus in Heart Transplantation: An Update [J].
Hirt, Stephan W. ;
Bara, Christoph ;
Barten, Markus J. ;
Deuse, Tobias ;
Doesch, Andreas O. ;
Kaczmarek, Ingo ;
Schulz, Uwe ;
Stypmann, Joeg ;
Haneya, Assad ;
Lehmkuhl, Hans B. .
JOURNAL OF TRANSPLANTATION, 2013, 2013
[8]  
Huiras P, 2011, REV HLTH CARE, V2, P229
[9]   UV-visible spectroscopy as an alternative to liquid chromatography for determination of everolimus in surfactant-containing dissolution media: A useful approach based on solid-phase extraction [J].
Kamberi, Marika ;
Thu-Ngoc Tran .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2012, 70 :94-100
[10]   A sensitive high-throughput HPLC assay for simultaneous determination of everolimus and clobetasol propionate [J].
Marika, Kamberi ;
Katherine, Fu ;
Jianmin, Lu ;
Mike, Chemaly G. ;
Debra, Feder .
JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2008, 46 (01) :23-29